DOCSLIB.ORG

Poster Session

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poster Session Neuropsychopharmacology (2012) 38, S314–S446 & 2012 American College of Neuropsychopharmacology All rights reserved 0893-133X/12 S314 www.neuropsychopharmacology.org Poster Session III Conclusions: In this pooled analysis, adjunctive aripiprazole Wednesday, December 05, 2012 resulted in significantly greater symptom improvement than placebo regardless of baseline severity. Change scores appeared greatest in the severe group but this may reflect the truncated W2. Treatment with Adjunctive Aripiprazole Results in range in the mild group. The greater response with adjunctive Significant Improvement Compared with Continued aripiprazole demonstrates the utility of this strategy to manage Antidepressant Monotherapy in Patients with Mild, Moderate, depression in a wide spectrum of patients. and Severe Major Depressive Disorder References 1. Thase ME, et al. Examning the efficacy of adjunctive J Craig. Nelson*, Thomas D. Stewart, Ainslie Hatch, aripiprazole in major depressive disorder: a pooled analysis of 2 Kimberly Largay, Elizabeth E. Bellochio, Sabrina V. Marler, studies. Prim Care Companion J Clin Psychiatry. 2008;10:440-7.2. Ross A. Baker, John Sheehan, Robert M. Berman Berman RM, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with University of California, San Francisco, California inadequate response to antidepressants. CNS Spectr. 2009;14: 197-206.3. Kearns NP, et al. A comparison of depression rating Background: The severity of a patient’s depressive symptoms scales. Brit J Psychiat. 1982;141:45-9. may inform treatment decisions. However, current treatment Keywords: aripiprazole, depression, antidepressants, MADRS, guidelines are based on trial data that group patients of varying treatment degrees of severity together. To better understand the appropriate Disclosure: J. Nelson, Part 1: Honoraria from Eli Lilly Global, patient for adjunctive aripiprazole in major depressive disorder Lundbeck, Otsuka Asia, Schering Plough/Merck (Asia); consultant (MDD), this post-hoc analysis pooled data from 3 similar, 1,2 for Bristol-Myers Squibb, Cenestra Health, Corcept, Covidien, Eli randomized trials, and stratified patients based on published Lilly, Forest, Lundbeck, Medtronics, Merck, Mylan (Dey Pharma), severity cut-offs on the Montgomery A˚ sberg Depression Rating 3 Orexigen, Otsuka, Pfizer, Sunovion, served on advisory boards for Scale (MADRS). Avanir, Bristol-Myers Squibb, Eli Lilly, Labopharm, Mylan (Dey Methods: These trials enrolled patients with an inadequate Pharma), and Otsuka, Part 2: Honoraria from Eli Lilly Global, response to 1-3 trials of antidepressant therapy (ADT). Each study Lundbeck, Otsuka Asia, Schering Plough/Merck (Asia); consultant had an 8-week prospective ADT phase (Phase B), followed by a for Bristol-Myers Squibb, Cenestra Health, Corcept, Covidien, Eli 6-week randomized phase (Phase C) of adjunctive aripiprazole Lilly, Forest, Lundbeck, Medtronics, Merck, Mylan (Dey Pharma), versus continued antidepressant monotherapy + placebo for Orexigen, Otsuka, Pfizer, Sunovion, served on advisory boards for patients with an inadequate response during the prospective phase. Avanir, Bristol-Myers Squibb, Eli Lilly, Labopharm, Mylan (Dey Inadequate response to ADT monotherapy was defined as o50% Pharma), and Otsuka, Part 3: n/a, Part 4: n/a; T. Stewart, Part 1: reduction in the 17-item Hamilton Rating Scale for Depression Speaker for Bristol-Myers Squibb Co., and Otsuka Pharmaceutical (HAM-D-17) total score, HAM-D-17 total score X14, and Clinical Part 1: Global Impressions-Improvement (CGI-I) score X3. For this post- Co., Ltd.; A. Hatch, Employee of Otsuka Pharmaceutical Part 2: hoc analysis, patients were stratified at the beginning of Phase C by Development & Commercialization, Inc., Employee of Otsuka Pharmaceutical Development & Commercialization, Inc.; MADRS total score into 3 groups: mild (MADRS total score p24), Part 1: moderate (MADRS total score ¼ 25-30), and severe (MADRS total K. Largay, Employee of Otsuka Pharmaceutical Develop- Part 2: score X31). During Phase C, aripiprazole was flexibly dosed with a ment & Commercialization, Inc., Employee of Otsuka target of 10 mg/day. Patients were initiated at 5 mg/day (could Pharmaceutical Development & Commercialization, Inc.; E. Bellochio, Part 1: Employee of Bristol-Myers Squibb Co., Part 2: decrease to 2 mg/day for tolerability) and increased to 10 mg/day Part 3: (could decrease to 5 mg/day for tolerability) at the end of Week 1; Employee of Bristol-Myers Squibb Co., Employee of Bristol- Part 1: the maximum dose was 20 mg/day. Change in MADRS total score Myers Squibb Co.; S. Marler, Employee of Bristol-Myers Squibb Co., Part 2: Employee of Bristol-Myers Squibb Co., Part 3: for adjunctive aripiprazole and adjunctive placebo was assessed at Part 1: the end of 6 weeks using last observation carried forward (LOCF). Employee of Bristol-Myers Squibb Co.; R. Baker, Employee Results: Baseline demographics across the three groups appeared of Otsuka Pharmaceutical Development and Commercialization, Part 2: similar. At the beginning of Phase C, in the aripiprazole group, 224 Inc, Employee of Otsuka Pharmaceutical Development and Commercialization, Inc, Part 3: Employee of Otsuka Pharmaceu- (41%), 206 (38%), and 110 (20%) patients were considered mild, Part 1: moderate, or severe, respectively; in the placebo group, it was tical Development and Commercialization, Inc; J. Sheehan, Part 2: 191 (36%), 179 (34%), and 155 (30%) patients, respectively. Employee of Bristol-Myers Squibb Co., Employee of Bristol- Part 3: At the end of 6 weeks, mean changes in MADRS total score Myers Squibb Co., Employee of Bristol-Myers Squibb Co.; R. Berman, Part 1: Employee of Bristol-Myers Squibb Co., Part 2: between aripiprazole and placebo were significantly different in all three severity groups: mild À7.9 aripiprazole vs. À5.4 placebo Employee of Bristol-Myers Squibb Co. (P ¼ 0.0005); moderate À9.5 aripiprazole vs. À6.3 placebo (P ¼ 0.0001); severe À11.9 aripiprazole vs. À7.4 placebo (P ¼ 0.0001). Statistically significantly differences between aripi- W3. Genomic Predictors of Response to Antidepressant prazole and placebo first appeared at Week 1 (mild or severe) or Treatment in Geriatric Depression Using Genome-wide Week 2 (moderate). In all three groups, the endpoint effect size of Expression Analyses: A Pilot Study aripiprazole treatment was moderate (0.334-0.483). Similarly, mean Helen Lavretsky*, Ascia Eskin, Stanley Nelson, Steve Cole percent improvement in MADRS total score between aripiprazole UCLA, Los Angeles, California and placebo were significantly different in all three severity groups: mild -38% aripiprazole vs. -26% placebo (P ¼ 0.0008); moderate - Background: Depression and antidepressant response are asso- 35% aripiprazole vs. -23% placebo (P ¼ 0.0001); severe -35% ciated with leukocyte gene transcriptional alterations. The present aripiprazole vs. ¼ 22% placebo (P ¼ 0.0002). Adjunctive aripipra- pilot study examined immune cell gene expression with anti- zole was well tolerated across the severity groups, with no trends in depressant treatment in geriatric depression. the proportion of patients reporting an adverse event (AE) based Methods: Genome-wide transcriptional profiles were collected on severity; the most common AEs in the aripiprazole-treated from peripheral blood leukocytes sampled at baseline and 16-week groups were akathisia and restlessness. follow-up from 37 older adults with major depression who were ACNP 51st Annual Conference Abstracts S315 randomized to methylphenidate + citalopram; citalopram + place- Methods: Seventy two cocaine-dependent individuals who were bo; or methylphenidate + placebo. Methylphenidate dose ranged not seeking treatment at the time of enrollment in the study were between 10-40 mg per day, and citalopram dose was 20-40 mg per randomly assigned to receive placebo (n ¼ 15), rivastigmine 3 mg day. Genome-wide transcriptional profiling was carried out in the (n ¼ 14), rivastigmine 6 mg (n ¼ 14), huperzine A 0.4 mg (n ¼ 15), peripheral blood mononuclear cell samples obtained at baseline or huperzine A 0.8 mg (n ¼ 14). Urinanalysis was used to confirm and post-intervention. Promoter-based bioinformatics analyses abstinence from cocaine on the day of admission and during the tested the hypothesis that observed transcriptional alterations were next 7 days. The baseline neurocognitive assessment, which structured by transcription factors implicated in dopaminergic, included measures of attention/information processing (as mea- serotonergic, and neuroplastic pathways. sured by the Continuous Performance Task), verbal learning Results: 25 responder and 12 non-responders gene expression episodic memory (as measured by the Hopkins Verbal Learning profiles were analyzedIn the analyses of covariance controlling for Test), and working memory (as measured by the Dual N-Back treatment group, 2 gene transcripts showed systematic up- Task), was conducted immediately after the washout phase and regulation in non-responders at baseline. Up-regulated genes at prior to the administration of study medication (Day 0). The baseline in non-responders compared to non-responders included follow-up assessment was conducted on Day 8 after participants 1) CA1 carbonic anhydrase gene on chromosome 8 involved in had received rivastigmine, huperzine A, or placebo for seven days reversible hydration of CO2 and respiratory function (fold change (Day 2-8). 2.54; P ¼ 0.03); 2) SNCA -alpha-synuclein
Load more

Recommended publications
  • Artaxerxes II
    Artaxerxes II John Shannahan BAncHist (Hons) (Macquarie University) Thesis submitted for the degree of Doctor of Philosophy. Department of Ancient History, Macquarie University. May, 2015. ii Contents List of Illustrations v Abstract ix Declaration xi Acknowledgements xiii Abbreviations and Conventions xv Introduction 1 CHAPTER 1 THE EARLY REIGN OF ARTAXERXES II The Birth of Artaxerxes to Cyrus’ Challenge 15 The Revolt of Cyrus 41 Observations on the Egyptians at Cunaxa 53 Royal Tactics at Cunaxa 61 The Repercussions of the Revolt 78 CHAPTER 2 399-390: COMBATING THE GREEKS Responses to Thibron, Dercylidas, and Agesilaus 87 The Role of Athens and the Persian Fleet 116 Evagoras the Opportunist and Carian Commanders 135 Artaxerxes’ First Invasion of Egypt: 392/1-390/89? 144 CHAPTER 3 389-380: THE KING’S PEACE AND CYPRUS The King’s Peace (387/6): Purpose and Influence 161 The Chronology of the 380s 172 CHAPTER 4 NUMISMATIC EXPRESSIONS OF SOLIDARITY Coinage in the Reign of Artaxerxes 197 The Baal/Figure in the Winged Disc Staters of Tiribazus 202 Catalogue 203 Date 212 Interpretation 214 Significance 223 Numismatic Iconography and Egyptian Independence 225 Four Comments on Achaemenid Motifs in 227 Philistian Coins iii The Figure in the Winged Disc in Samaria 232 The Pertinence of the Political Situation 241 CHAPTER 5 379-370: EGYPT Planning for the Second Invasion of Egypt 245 Pharnabazus’ Invasion of Egypt and Aftermath 259 CHAPTER 6 THE END OF THE REIGN Destabilisation in the West 267 The Nature of the Evidence 267 Summary of Current Analyses 268 Reconciliation 269 Court Intrigue and the End of Artaxerxes’ Reign 295 Conclusion: Artaxerxes the Diplomat 301 Bibliography 309 Dies 333 Issus 333 Mallus 335 Soli 337 Tarsus 338 Unknown 339 Figures 341 iv List of Illustrations MAP Map 1 Map of the Persian Empire xviii-xix Brosius, The Persians, 54-55 DIES Issus O1 Künker 174 (2010) 403 333 O2 Lanz 125 (2005) 426 333 O3 CNG 200 (2008) 63 333 O4 Künker 143 (2008) 233 333 R1 Babelon, Traité 2, pl.
    [Show full text]
  • Download Resume
    Curriculum Vitae Full Name: David M. Marks, M.D. Contact: [email protected] Mobile (619) 822-7117 Credentials: Diplomate, American Board of Psychiatry and Neurology (Psychiatry) Subspecialty Certification in Psychosomatic Medicine Diplomate, American Board of Pain Medicine Position Title: Associate Professor Department of Psychiatry and Behavioral Sciences Department of Community and Family Medicine Duke University Medical Center Duke Clinical Research Institute Duke Pain and Palliative Care Clinic Education: Institution & Location Degree Year Conferred Field of Study University of California at San Diego Fellowship 1999 - 2000 Consultation and San Diego, CA Liaison Psychiatry Medical College of Pennsylvania / Senior 1998 - 1999 Psychiatry Clinical Neuroscience Research Unit Resident Philadelphia, PA University of California at San Diego Resident 1995 - 1998 Psychiatry San Diego, CA University of Texas Medical Branch M.D. 1995 Galveston, TX Rice University B.A. 1991 Psychology Houston, TX Research and Professional Experience: Position Institution/Employer & Location Dates of Employment Attending Faculty Physician Duke Pain and Palliative Care Clinic 09/08-present (Chronic Pain Management) Attending Faculty Physician Duke University Medical Center, 07/06-present Inpatient Psychiatric Service, Emergency Service, Consultation/Liaison Service Attending Faculty Physician Durham Regional Hospital, 09/08-07/11 Consultation/Liaison Service Medical Director, Inpatient and Duke University Medical Center 07/06 – 02/07 Emergency Psychiatry Services Medical Director, CNS Division EStudy Site 05/05 -- 07/06 La Mesa, Oceanside, National City CA Chief Executive Officer/Medical Optimum Health Services 01/02 – 05/05 Director La Mesa, Oceanside CA Chief of Staff Alvarado Parkway Institute 01/04 – 01/05 1 La Mesa, CA Page _____________________________________________________________________ David M.
    [Show full text]
  • Centre for Reviews and Dissemination
    Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta- analysis Leucht S, Corves C, D Arbter, Engel R R, Li C, Davis J M CRD summary The authors concluded that amisulpride, clozapine, olanzapine and risperidone can be effective in treating schizophrenia patients. Second-generation antipsychotic drugs can also result in fewer extrapyramidal side effects, but can induce weight gain. The authors' conclusions reflected the evidence presented, but some potential methodological flaws in the review process meant that the extent to which those conclusions were reliable was unclear. Authors' objectives To compare the effects of first and second-generation antipsychotic drugs in schizophrenia patients. Searching The search for eligible studies was started in 2005, including MEDLINE to October 2006, Cochrane Schizophrenia Group's Specialised Register and the US Food and Drugs Administration website. Search terms were reported and there were no language restrictions. Previous reviews were searched for additional relevant studies. Study selection Randomised controlled trials (RCTs) of oral second-generation antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine) compared with first-generation drugs in patients with schizophrenia or related disorders (schizoaffective, schizophreniform or delusional disorders) irrespective of diagnostic criteria were eligible for inclusion in the review. The optimum doses of second-generation drugs were selected
    [Show full text]
  • New Drug Evaluation Monograph Template
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update: Second Generation Antidepressant Medications Month/Year of Review: May 2014 Last Oregon Review: April 2012 PDL Classes: Psychiatric: Antidepressants Source Document: OSU College of Pharmacy New drug(s): vortioxetine (Brintellix®) Manufacturer: Takeda & Lundbeck/Forest levomilnacipran extended-release (Fetzima®) Dossier Received: Yes/Pending Current Status of Voluntary PDL Class: Preferred Agents: BUPROPION HCL TABLET/TABLET ER, CITALOPRAM TABLET/SOLUTION, FLUOXETINE CAPSULE/SOLUTION/TABLET, FLUVOXAMINE, MIRTAZEPINE TAB RAPDIS/TABLET, PAROXETINE TABLET, SERTRALINE ORAL CONC/TABLET, VENLAFAXINE TABLET, VENLAFAXINE ER Non-Preferred Agents: BUPROPRION XL, DESVENLAFAXINE (PRISTIQ ER), DULOXETINE (CYMBALTA®), ESCITALOPRAM, FLUOXETINE DF (PROZAC® WEEKLY), NEFAZODONE, PAROXETINE HCL (PAXIL CR®), SELEGILINE PATCH (ENSAM®), VILAZODONE (VIIBRYD®), OLANZAPINE/FLUOXETINE (SYMBYAX®) Status of the Voluntary Mental Health Preferred Drug List Currently, all antidepressants are available without prior authorization for non-preferred placement. Oregon law prohibits traditional methods of PDL enforcement on mental health drugs. Second generation antidepressants have been reviewed for clinical efficacy and safety and specific agents were chosen as clinically preferred; this eliminates a copay. Oregon’s Medicaid program currently
    [Show full text]
  • 5227-2-Kuchuk Asya-2-Cughrafyasi
    CHARLES TEXIER 00 00 II�J[J�liJII( A§YA Coğrafyası,Tarihi ve Arkeolojisi Çeviren Ali SUAT Latin Harflerine Aktaran Sadeleştiren Prof. Dr. Yard. Doç. Dr. Kazım Yaşar KOPRAMAN Musa YILDIZ ENFORMASYON VE DOKÜMANTASYON HİZMETLERİ VAKFI Ankara - 2002 © 2002 Enformasyon ve Dokümantasyon Hizmetleri Vakfı 7. Cadde, Kültür Sitesi, No: 104 06370 Batıkent Ankara/ TÜRKİYE Tel: (+90.312) 354 62 66 • Faks: (+90.312) 354 64 63 e-mail: edhvakfı@ada.net.tr • www.edhvakfi.org.tr Eserin Orijinal Adı: Asi e Mineure; Description Geographique, Historique et Archeologique des Provinces et des Villes de la Chersonnese d' Asie. Paris, Typographie de Firmin Didot Freres, Fils et C., Editeurs Imprimeurs de L' Institut de France, 1862, 1882. Eserin Arap Hart'liTürkçe Adı: Kü çük Asya; Coğrafyaya, Tarihe, Asar-ı Atikaya Ait Tarif. İstanbul, Matbaa-i Amire J 92: 1924, 3 c. Proje ve Koordinasyon Hasan DUMAN Latin Harflerine Aktaran Prof. Dr. Kazım Ya§ar KOPRAMAN Gazi Üniv. Fen-Ed. Fak Sadeleştiren Yard. Doç. Dr. Musa YILDIZ Gazi Üniv. Eğt. Fak. Katkıda Bulunanlar Prof. Dr. Semavi EYİCE istanbul Üniv. Ed. Fak. Prof. Dr. Mesut ELİBÜYÜK Ankara Üniv. D.T.C. Fak. Yard. Doç. Dr. Esma İNCE Gazi Üniv. Eğt. Fak. Yard.Doç. Dr. Kenan BİLİCİ Ankara Üniv. D.T.C. Fak. Yard. Doç. Dr. Yücel ŞENYURT Gazi Üniv. Fen-Ed. Fak. Yard. Doç. Dr. Kamil AKARSU Gazi Üniv. Eğt. Fak. Murat ÖNGÖREN Teknik Yardımcı Eserin tüm yayın hakları saklıdır. Hiç bir şekilde gravürler de dahil olmak üzere kısmen de olsa herhangi bir yöntemle kopye edilip, çoğaltı lamaz, yayınlanamaz. ISBN 975-7473-12-X Takım/Set ISBN 975-7473-13-8 I.
    [Show full text]
  • Pharmacotherapy, Drug-Drug Interactions and Potentially
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.31.21254518; this version posted April 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders Jan Wolff1,2,3, Pamela Reißner4, Gudrun Hefner5, Claus Normann2, Klaus Kaier6, Harald Binder6, Christoph Hiemke7, Sermin Toto8, Katharina Domschke2, Michael Marschollek1, Ansgar Klimke4,9 1 Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Germany. 2 Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3 Evangelical Foundation NeuerKerode, Germany. 4 Vitos Hochtaunus, Friedrichsdorf, Germany. 5 Vitos Clinic for Forensic Psychiatry, Eltville, Germany 6 Institute of Medical Biometry and Statistics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany. 7 Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Germany. 8 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Germany. 9 Heinrich-Heine-University Düsseldorf, Germany. ___ Correspondence Dr. Jan Wolff, Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Hannover, Germany. Address: Karl- Wiechert-Allee 3, 30625 Hannover. Email: [email protected], wolff.jan@mh- hannover.de, ORCID: https://orcid.org/0000-0003-2750-0606 Key words (MeSH) Depression, Polypharmacy, Antidepressants, Hospitals, Drug Interactions, Psychiatry NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Plinius Senior Naturalis Historia Liber V
    PLINIUS SENIOR NATURALIS HISTORIA LIBER V 1 Africam Graeci Libyam appellavere et mare ante eam Libycum; Aegyptio finitur, nec alia pars terrarum pauciores recipit sinus, longe ab occidente litorum obliquo spatio. populorum eius oppidorumque nomina vel maxime sunt ineffabilia praeterquam ipsorum linguis, et alias castella ferme inhabitant. 2 Principio terrarum Mauretaniae appellantur, usque ad C. Caesarem Germanici filium regna, saevitia eius in duas divisae provincias. promunturium oceani extumum Ampelusia nominatur a Graecis. oppida fuere Lissa et Cottae ultra columnas Herculis, nunc est Tingi, quondam ab Antaeo conditum, postea a Claudio Caesare, cum coloniam faceret, appellatum Traducta Iulia. abest a Baelone oppido Baeticae proximo traiectu XXX. ab eo XXV in ora oceani colonia Augusti Iulia Constantia Zulil, regum dicioni exempta et iura in Baeticam petere iussa. ab ea XXXV colonia a Claudio Caesare facta Lixos, vel fabulosissime antiquis narrata: 3 ibi regia Antaei certamenque cum Hercule et Hesperidum horti. adfunditur autem aestuarium e mari flexuoso meatu, in quo dracones custodiae instar fuisse nunc interpretantur. amplectitur intra se insulam, quam solam e vicino tractu aliquanto excelsiore non tamen aestus maris inundant. exstat in ea et ara Herculis nec praeter oleastros aliud ex narrato illo aurifero nemore. 4 minus profecto mirentur portentosa Graeciae mendacia de his et amne Lixo prodita qui cogitent nostros nuperque paulo minus monstrifica quaedam de iisdem tradidisse, praevalidam hanc urbem maioremque Magna Carthagine, praeterea ex adverso eius sitam et prope inmenso tractu ab Tingi, quaeque alia Cornelius Nepos avidissime credidit. 5 ab Lixo XL in mediterraneo altera Augusta colonia est Babba, Iulia Campestris appellata, et tertia Banasa LXXV p., Valentia cognominata.
    [Show full text]
  • The Effect of White Noise on Short- and Long-Term
    THE EFFECT OF WHITE NOISE ON SHORT- AND LONG-TERM RECALL IN HYPERACTIVE BOYS by Norma Jean Arbuckle Dissertation submitted to the Faculty of the Graduate School of the University of Maryland in partial fulfillment of the requirements for the degree of Doctor of Philosophy 1977 ABSTRACT Title of Dissertation: The Effect of White Noise on Short- and Long-Term Recall in Hyperactive Boys Norma Jean Arbuckle, Doctor of Philosophy, 1977 Dissertation directed by: Marie S. Davidson, Assistant Professor, Institute for Child Study The purpose of this research investigation was to determine whether an auditory arouser in the form of 2-minute bursts of 75 decibels of white noise (WN) might be used to facilitate short- and long-term re- call for hyperactive boys. An attempt was made to determine whether the stimulus was most effective if it was presented (a) before acquisi- tion, (b) before the recall tests, or (c) both before acquisition and before the recall tests. Hyperactivity was operationally defined as a score of eight or more on the Conners' Teacher's Questionnaire. The subjects for the study were 36 boys who had received the criterion score or more on the Ques- tionnaire which had been completed by the regular classroom teacher of each child. The boys were between the ages of 8.50 and 12.75 years. Ten hypotheses were tested using two types of tasks. A silently read paragraphs task consistently preceded a tape-recorded paragraphs task. Each task was followed by the administration of two halves of a test. The first half of the test for each task was given at a 2- minute interval and the second half of the test for each task was given at a 24-hour interval.
    [Show full text]
  • Current Phase III Clinical Trials
    Toolbox: Current phase III clinical trials Tiffany-Jade Kreys, PharmD1 1Assistant Professor of Pharmacy Practice University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas KEYWORDS clinical trials, depression, bipolar, schizophrenia, medications Table 1. Novel Agents for Major Depression, Bipolar Disorder, and/or Schizophrenia Product Name Sponsor Indication Mechanism of Action (previous name) Downloaded from http://meridian.allenpress.com/mhc/article-pdf/2/6/138/2094102/mhc_n129046.pdf by guest on 26 September 2021 Amitifadine Euthymics MDD Triple Reuptake Inhibitor (EB-1010) Bioscience (1:2:8 ratio of serotonin: norepinephrine: dopamine inhibition) Bitopertin Roche Schizophrenia Glycine reuptake inhibitor (RG1678) Enhances NMDA receptor activity Brexpiprazole Lundbeck MDD, Claimed to have "broad activity across multiple monoamine (OPC-34712) Otsuka America Schizophrenia systems and exhibits reduced partial agonist activity at D2 Pharmaceuticals receptors and enhanced affinity for specific serotonin receptors" Cariprazine Forest Laboratories BPAD, MDD adjunct D3-preferring/D2 receptor partial agonist (RGH-188) therapy, Schizophrenia Citalopram/ PharmaNeuro- MDD 5HT2A/D4 antagonist Pipamperone Boost (PNB01) Edivoxetine Eli Lilly MDD adjunct therapy Norepinephrine reuptake inhibitor (LY2216684) Vortioxetine Lundbeck MDD In vitro studies: 5HT3 and 7 receptor antagonist, 5HT1B partial (LUAA21004) Takeda agonist, 5HT1A agonist, serotonin transporter inhibitor Pharmaceuticals In vivo: Increases serotonin, norepinephrine, dopamine,
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • AHRQ Healthcare Horizon Scanning System – Status Update
    AHRQ Healthcare Horizon Scanning System – Status Update Horizon Scanning Status Update: January 2014 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290201000006C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 January 2014 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290201000006C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. A novel intervention may not appear in this report simply because the System has not yet detected it. The list of novel interventions in the Horizon Scanning Status Update Report will change over time as new information is collected. This should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual target technology reports are developed for those that appear to be closer to diffusion into practice in the United States. A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in the horizon scanning, assessing the leads or topics, or provide opinions regarding potential impact of interventions.
    [Show full text]